HRP20100664T1 - Upotreba 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-diona u lijecenju limfoma stanica plasta - Google Patents
Upotreba 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-diona u lijecenju limfoma stanica plasta Download PDFInfo
- Publication number
- HRP20100664T1 HRP20100664T1 HR20100664T HRP20100664T HRP20100664T1 HR P20100664 T1 HRP20100664 T1 HR P20100664T1 HR 20100664 T HR20100664 T HR 20100664T HR P20100664 T HRP20100664 T HR P20100664T HR P20100664 T1 HRP20100664 T1 HR P20100664T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino
- dione
- piperidine
- oxo
- dihydroisoindol
- Prior art date
Links
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 title claims abstract 19
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 title claims 4
- 239000013543 active substance Substances 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 102100039064 Interleukin-3 Human genes 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000011443 conventional therapy Methods 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
3-(4-Amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion, naznacen time sto je namijen upotrebi u lijecenju limfom stanica plasta kod ljudi. Patent sadrzi jos 14 patentnih zahtjeva.
Claims (15)
1. 3-(4-Amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion, naznačen time što je namijen upotrebi u liječenju limfom stanica plašta kod ljudi.
2. 3-(4-Amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion, namijen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što limfom stanica plašta je recidivirao, refraktaran ili otporan na konvencionalnu terapiju.
3. 3-(4-Amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion, namijen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što ga se pripravlja za primjenu u količini od 1 do 50 mg dnevno.
4. 3-(4-Amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion, namijen upotrebi u skladu s patentnim zahtjevom 3, naznačen time što ga se pripravlja za primjenu u količini od otprilike 10, 15, 20 ili 25 mg dnevno.
5. 3-(4-Amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion, namijen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što ga se pripravlja za primjenu u količini od otprilike 25 mg dnevno.
6. 3-(4-Amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion, namijen upotrebi u skladu s patentnim zahtjevom 3, naznačen time što 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion je enantiomerno čist.
7. 3-(4-Amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion, namijen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion je S ili R enantiomer.
8. 3-(4-Amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion, namijen upotrebi u skladu s patentnim zahtjevom 3, naznačen time što ga se pripravlja za oralnu primjenu.
9. 3-(4-Amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion, namijen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što ga se pripravlja za primjenu u obliku kapsule ili tablete.
10. 3-(4-Amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion, namijen upotrebi u skladu s patentnim zahtjevom 3, naznačen time što ga se pripravlja za primjenu u trajanju od 21 dan, za čim slijedi sedmodnevni odmor, u ciklusu od 28 dana.
11. 3-(4-Amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion, namijen upotrebi u skladu s patentnim zahtjevom 10, naznačen time što ga se pripravlja za primjenu u količini od otprilike 25 mg dnevno, u trajanju od 21 dan, za čim slijedi sedmodnevni odmor, u ciklusu od 28 dana.
12. 3-(4-Amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion, namijen upotrebi u skladu s patentnim zahtjevom 11, naznačen time što ga se pripravlja za primjenu u kombinaciji s rituksimabom, u količini od 375 mg/m2, intravenskom infuzijom, jednom tjedno.
13. 3-(4-Amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion i drugo aktivno sredstvo, naznačeni time što su namijeni upotrebi u liječenju limfom stanica plašta.
14. 3-(4-Amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion i drugo aktivno sredstvo, namijeni upotrebi u skladu s patentnim zahtjevom 13, naznačeni time što drugo aktivno sredstvo je protutijelo, hematopoetski čimbenik rasta, citokin, sredstvo protiv raka, antibiotik, inhibitor cox-2, imunomodulacijsko sredstvo, imunosupresivno sredstvo, kortikosteroid, ili farmakološki aktivni mutant ili njegov derivat, gdje se mutant razlikuje od prirodnog oblika proteina jednim ili više aminokiselinskih ostataka i/ili medostatkom ugljikohidratnih ostataka, te gdje derivat je pegilirani derivat ili fuzijski protein prirodnog proteina.
15. 3-(4-Amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion i drugo aktivno sredstvo, namijeni upotrebi u skladu s patentnim zahtjevom 13, naznačeni time što drugo aktivno sredstvo je rituksimab.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83575206P | 2006-08-03 | 2006-08-03 | |
| PCT/US2007/017343 WO2008019065A1 (en) | 2006-08-03 | 2007-08-02 | Use of 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment of mantle cell lymphomas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100664T1 true HRP20100664T1 (hr) | 2011-01-31 |
Family
ID=38691762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100664T HRP20100664T1 (hr) | 2006-08-03 | 2010-12-02 | Upotreba 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-diona u lijecenju limfoma stanica plasta |
Country Status (26)
| Country | Link |
|---|---|
| US (7) | US20080038263A1 (hr) |
| EP (1) | EP2046331B1 (hr) |
| JP (2) | JP5465005B2 (hr) |
| KR (2) | KR20140082859A (hr) |
| CN (2) | CN102908346A (hr) |
| AR (1) | AR062265A1 (hr) |
| AT (1) | ATE486601T1 (hr) |
| AU (1) | AU2007282027B2 (hr) |
| CA (2) | CA2659774C (hr) |
| CL (1) | CL2007002218A1 (hr) |
| CY (1) | CY1110989T1 (hr) |
| DE (1) | DE602007010303D1 (hr) |
| DK (1) | DK2046331T3 (hr) |
| ES (1) | ES2351069T3 (hr) |
| HR (1) | HRP20100664T1 (hr) |
| IL (1) | IL196885A (hr) |
| ME (1) | ME01937B (hr) |
| MX (1) | MX2009001268A (hr) |
| PE (1) | PE20081311A1 (hr) |
| PL (1) | PL2046331T3 (hr) |
| PT (1) | PT2046331E (hr) |
| RS (1) | RS51567B (hr) |
| RU (1) | RU2446804C2 (hr) |
| SI (1) | SI2046331T1 (hr) |
| TW (1) | TWI430797B (hr) |
| WO (1) | WO2008019065A1 (hr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2007002218A1 (es) * | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
| WO2009114601A2 (en) * | 2008-03-11 | 2009-09-17 | Dr. Reddy's Laboratories Ltd. | Preparation of lenalidomide |
| US20110280913A1 (en) * | 2008-07-31 | 2011-11-17 | The Ohio State University | Methods and Compositions for Delivering Therapeutic Agents in the Treatment of B-Cell Related Disorders |
| EP2544687A1 (en) * | 2010-03-12 | 2013-01-16 | Celgene Corporation | Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor |
| NZ630040A (en) | 2012-05-03 | 2016-10-28 | Janssen Sciences Ireland Uc | Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections |
| CN104004056B (zh) * | 2014-06-23 | 2016-08-17 | 王方杰 | 一种关于Cyclin D蛋白抑制剂多肽及其应用 |
| CN104031122B (zh) * | 2014-06-23 | 2016-05-11 | 常州市肿瘤医院 | 有关Cyclin D蛋白抑制剂多肽及其应用 |
| CN104004060B (zh) * | 2014-06-23 | 2016-04-13 | 重庆医科大学 | Cyclin D蛋白抑制剂多肽及其应用 |
| US11584733B2 (en) | 2017-01-09 | 2023-02-21 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| WO2018129533A1 (en) | 2017-01-09 | 2018-07-12 | Shuttle Pharmaceuticals, Llc | Selective histone deacetylase inhibitors for the treatment of human disease |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| US11407723B2 (en) | 2018-01-09 | 2022-08-09 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| JP2021519337A (ja) | 2018-03-26 | 2021-08-10 | シー４ セラピューティクス， インコーポレイテッド | Ｉｋａｒｏｓの分解のためのセレブロン結合剤 |
| EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS |
| EP3846800A4 (en) | 2018-09-04 | 2022-08-24 | C4 Therapeutics, Inc. | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 |
| WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
| WO2020181232A1 (en) | 2019-03-06 | 2020-09-10 | C4 Therapeutics, Inc. | Heterocyclic compounds for medical treatment |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5A (en) * | 1836-08-10 | Thomas blancharjq | ||
| US2845770A (en) * | 1956-09-26 | 1958-08-05 | William F Fessler | Baled hay rack and carrier |
| US3536809A (en) * | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3636809A (en) * | 1969-07-10 | 1972-01-25 | Nippon Musical Instruments Mfg | Stringed musical instrument |
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5391485A (en) * | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) * | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| AU1531492A (en) * | 1991-02-14 | 1992-09-15 | Rockefeller University, The | Method for controlling abnormal concentration tnf alpha in human tissues |
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5360352A (en) * | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6114355A (en) * | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
| US6228879B1 (en) * | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
| US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US20010056114A1 (en) * | 2000-11-01 | 2001-12-27 | D'amato Robert | Methods for the inhibition of angiogenesis with 3-amino thalidomide |
| US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| IT1270594B (it) * | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5731325A (en) * | 1995-06-06 | 1998-03-24 | Andrulis Pharmaceuticals Corp. | Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents |
| US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US5798368A (en) * | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
| WO1998003502A1 (en) | 1996-07-24 | 1998-01-29 | Celgene Corporation | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and method of reducing tnf-alpha levels |
| HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| DK0918746T3 (da) * | 1996-08-12 | 2003-08-04 | Celgene Corp | Immunterapeutiske midler og deres anvendelse til reduktion af cytokinniveauer |
| ATE305301T1 (de) * | 1996-11-05 | 2005-10-15 | Childrens Medical Center | Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid |
| US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
| US5874448A (en) * | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
| TR200101503T2 (tr) * | 1998-03-16 | 2002-06-21 | Celgene Corporation | 2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı |
| US6673828B1 (en) * | 1998-05-11 | 2004-01-06 | Children's Medical Center Corporation | Analogs of 2-Phthalimidinoglutaric acid |
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| US20030013739A1 (en) * | 1998-12-23 | 2003-01-16 | Pharmacia Corporation | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia |
| KR100672892B1 (ko) * | 1999-03-18 | 2007-01-23 | 셀진 코오퍼레이션 | 치환된 1-옥소- 및 1,3-디옥소이소인돌린스 및 염증성사이토킨 수치를 감소시키기 위한 약학적 조성물로서의이들의 사용 |
| US7182953B2 (en) * | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| US6326388B1 (en) * | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
| CA2319872C (en) * | 2000-02-02 | 2012-06-19 | Chun-Ying Huang | Pharmaceutical composition for the treatment of hepatocellular carcinoma |
| TR200202194T2 (tr) | 2000-03-17 | 2003-01-21 | Cell Therapeutics, Inc. | Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri |
| NZ521937A (en) * | 2000-03-31 | 2004-08-27 | Celgene Corp | Inhibition of cyclooxygenase-2 activity |
| WO2001087307A2 (en) * | 2000-05-15 | 2001-11-22 | Celgene Corp. | Compositions and methods for the treatment of cancer |
| US6458810B1 (en) * | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| NZ526683A (en) | 2000-11-30 | 2008-03-28 | Childrens Medical Center | Synthesis of 4-amino-thalidomide and its enantiomers that are suitable for inhibiting angiogenesis |
| US20020128228A1 (en) * | 2000-12-01 | 2002-09-12 | Wen-Jen Hwu | Compositions and methods for the treatment of cancer |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| EP1389203B8 (en) * | 2001-02-27 | 2010-03-10 | The Governement of the United States of America, represented by The Secretary Department of Health and Human services | Analogs of thalidomide as angiogenesis inhibitors |
| US7153867B2 (en) * | 2001-08-06 | 2006-12-26 | Celgene Corporation | Use of nitrogen substituted thalidomide analogs for the treatment of macular degenerator |
| US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| WO2003086373A1 (en) | 2002-04-12 | 2003-10-23 | Celgene Corporation | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds |
| CA2752140A1 (en) * | 2002-05-17 | 2003-11-27 | Celgene Corporation | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| CL2004001004A1 (es) * | 2003-05-19 | 2005-03-18 | Upjohn Co | Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple. |
| CL2007002218A1 (es) * | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
| US7893045B2 (en) * | 2007-08-07 | 2011-02-22 | Celgene Corporation | Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
-
2007
- 2007-07-31 CL CL200702218A patent/CL2007002218A1/es unknown
- 2007-08-01 TW TW096128250A patent/TWI430797B/zh active
- 2007-08-01 US US11/888,881 patent/US20080038263A1/en not_active Abandoned
- 2007-08-02 KR KR1020147014837A patent/KR20140082859A/ko not_active Application Discontinuation
- 2007-08-02 RU RU2009107535/15A patent/RU2446804C2/ru not_active IP Right Cessation
- 2007-08-02 MX MX2009001268A patent/MX2009001268A/es active IP Right Grant
- 2007-08-02 DK DK07811048.3T patent/DK2046331T3/da active
- 2007-08-02 CA CA2659774A patent/CA2659774C/en active Active
- 2007-08-02 CA CA2836006A patent/CA2836006A1/en not_active Abandoned
- 2007-08-02 DE DE602007010303T patent/DE602007010303D1/de active Active
- 2007-08-02 RS RS20100541A patent/RS51567B/en unknown
- 2007-08-02 WO PCT/US2007/017343 patent/WO2008019065A1/en active Application Filing
- 2007-08-02 ME MEP-2010-541A patent/ME01937B/me unknown
- 2007-08-02 EP EP07811048A patent/EP2046331B1/en active Active
- 2007-08-02 CN CN2012103235264A patent/CN102908346A/zh active Pending
- 2007-08-02 ES ES07811048T patent/ES2351069T3/es active Active
- 2007-08-02 SI SI200730446T patent/SI2046331T1/sl unknown
- 2007-08-02 CN CN200780036550.7A patent/CN101583359B/zh active Active
- 2007-08-02 AT AT07811048T patent/ATE486601T1/de active
- 2007-08-02 AU AU2007282027A patent/AU2007282027B2/en active Active
- 2007-08-02 PL PL07811048T patent/PL2046331T3/pl unknown
- 2007-08-02 JP JP2009522882A patent/JP5465005B2/ja active Active
- 2007-08-02 PT PT07811048T patent/PT2046331E/pt unknown
- 2007-08-02 KR KR1020097004393A patent/KR101483802B1/ko not_active IP Right Cessation
- 2007-08-03 PE PE2007001016A patent/PE20081311A1/es not_active Application Discontinuation
- 2007-08-03 AR ARP070103447A patent/AR062265A1/es unknown
-
2009
- 2009-02-03 IL IL196885A patent/IL196885A/en active IP Right Grant
- 2009-11-19 US US12/621,502 patent/US8741929B2/en active Active
-
2010
- 2010-12-02 HR HR20100664T patent/HRP20100664T1/hr unknown
- 2010-12-10 CY CY20101101137T patent/CY1110989T1/el unknown
-
2013
- 2013-08-15 JP JP2013168932A patent/JP2013256514A/ja not_active Withdrawn
-
2014
- 2014-05-30 US US14/291,364 patent/US20140271638A1/en not_active Abandoned
-
2016
- 2016-06-09 US US15/178,440 patent/US20170027923A1/en not_active Abandoned
-
2018
- 2018-05-18 US US15/984,018 patent/US20180263968A1/en not_active Abandoned
-
2019
- 2019-08-21 US US16/546,983 patent/US20190374529A1/en not_active Abandoned
-
2020
- 2020-05-13 US US15/930,845 patent/US20200276175A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100664T1 (hr) | Upotreba 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-diona u lijecenju limfoma stanica plasta | |
| JP2009545600A5 (hr) | ||
| JP2009510171A5 (hr) | ||
| JP2005530784A5 (hr) | ||
| TW200640455A (en) | Oral dosage form comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione | |
| CA2672000A1 (en) | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of lymphoma | |
| AP1954A (en) | Controlled release compositions comprising nimesulide. | |
| TW200635897A (en) | Piperidine derivatives and their use as anti-inflammatory agents | |
| GEP20125684B (en) | Dipeptidyl peptidase inhibitors weekly administration | |
| IL168061A (en) | Compound 3 - (4 - amino - 1 - oxo - 1, 3 - dihydro - isoindole - 2 - il) - piperidine - 2, 6 - deion for the use of the drug for the treatment and regulation of myelodysplastic symptoms | |
| NO20061978L (no) | Imidazopyridinsubstituerte tropanderivater med CCR5-reseptorantagonist aktivitet for behandling av HIV og inflammasjon | |
| EP1461015A4 (en) | COMPOSITIONS CONTAINING SEDATIVE ANTIHISTAMINES AND NON-SEDATIVE ANTIHISTAMINES | |
| AP1789A (en) | Tropane derivatives useful in therapy. | |
| NZ555466A (en) | 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators | |
| EA200701681A1 (ru) | Пероральная лекарственная форма, содержащая росиглитазон | |
| JP2006316075A5 (hr) | ||
| GEP20094680B (en) | Piperazinylpiperidine derivatives as chemokine receptor antagonists | |
| BR112012009857A2 (pt) | composições farmacêuticas sólidas contendo um inibidor de integrase | |
| Bakathir et al. | Effects of nicotine on bone during orthodontic tooth movement in male rats: Histological and immunohistochemical study | |
| EA200702648A1 (ru) | Фармацевтическая композиция, пригодная для введения один раз в день | |
| JP2009539916A5 (hr) | ||
| EA200701409A1 (ru) | Новая композиция | |
| YU81101A (sh) | Polimorfni oblici kristalnog citrata azabiciklo (2,2,2) oktan-3-amina i njihovih farmaceutskih kompozicija | |
| WO2009073146A3 (en) | Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders | |
| MA28930B1 (fr) | Derives pyridiniques d'indolin-2-one , leur preparation et leur application en therapeutique |